Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, two have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $6.2333.
IRWD has been the subject of several recent analyst reports. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 1st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th.
View Our Latest Report on Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Stock Performance
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $106.51 million during the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. Sell-side analysts forecast that Ironwood Pharmaceuticals will post 1.04 EPS for the current year.
Insiders Place Their Bets
In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider owned 313,680 shares of the company’s stock, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Julie Mchugh sold 21,571 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the sale, the director directly owned 250,749 shares of the company’s stock, valued at $935,293.77. This represents a 7.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.30% of the stock is owned by corporate insiders.
Institutional Trading of Ironwood Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC increased its position in shares of Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares during the last quarter. LSV Asset Management bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $30,000. Captrust Financial Advisors acquired a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $32,000. Jump Financial LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $34,000. Finally, DGS Capital Management LLC bought a new position in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $35,000.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
